Anti-malarial Drugs Market Size, Share & Trends Analysis Report, By Drug Class (Aryl Aminoalcohol Compounds, Antifolate Compounds, Artemisinin Compounds, Other), By Mechanism Of Action (Malaria, Prevention From Malaria), By Malaria Type (Plasmodium Falciparum, Plasmodium Vivax, Plasmodium Malaria, And Plasmodium Ovale) and By Region, And Segment Forecasts, Till : 2030

Report ID : AMR1004982 | Industries : Healthcare | Published On :January 2024 | Page Count : 245

Anti-malarial Drugs Market Size, Share & Trends Analysis Report, By Drug Class (Aryl Aminoalcohol Compounds, Antifolate Compounds, Artemisinin Compounds, Other), By Mechanism Of Action (Malaria, Prevention From Malaria), By Malaria Type (Plasmodium Falciparum, Plasmodium Vivax, Plasmodium Malaria, And Plasmodium Ovale) and By Region, And Segment Forecasts, Till – 2030

Market Overview

According to Analytical Market Research, the global Anti-malarial Drugs market estimated at USD 989.7 million in 2022 and which expected, at a compound annual growth rate (CAGR) of 3.90% from 2023 to 2030. Key players in the Anti-malarial Drugs market employ various strategies to maintain and enhance their market presence. These strategies help key players capture a significant market share and remain competitive in the dynamic Anti-malarial Drugs market. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated includes proficient analysis, predictive analysis, prescriptive analysis, cumulative analysis, and value chain analysis.

ANTI-MALARIAL DRUGS MARKET DYNAMICS: KEY DRIVERS & RESTRAINTS

Advances in Drug Research and Development
One significant driver in the anti-malarial drugs market is the continuous advancement in drug research and development. Ongoing efforts to discover and develop novel anti-malarial compounds, including new drug formulations and combination therapies, contribute to improved treatment options. Innovations in drug development enhance efficacy, reduce side effects, and address concerns related to drug resistance, thereby driving the growth of the anti-malarial drugs market.
Emergence of Drug Resistance
A notable restraint in the anti-malarial drugs market is the emergence of drug resistance. Malaria parasites can develop resistance to commonly used anti-malarial medications, reducing the effectiveness of treatment. The evolving resistance poses a challenge to malaria control efforts, impacting patient outcomes and necessitating a continuous search for new therapeutic options. Addressing drug resistance remains a critical concern and a potential limitation in the overall effectiveness of anti-malarial drugs.

How are Segments Performing in the Global Anti-malarial Drugs Market?

Anti-malarial Drugs Drug Class Segment Breakdown
According to Analytical Market Research, the Anti-malarial Drugs market by Drug Class is segmented into Aryl Aminoalcohol Compounds, Antifolate Compounds, Artemisinin Compounds, Other.
Anti-malarial Drugs Mechanism Of Action Segment Breakdown
According to Analytical Market Research, based on Mechanism Of Action, the market is segmented into Malaria, Prevention From Malaria.
Anti-malarial Drugs Malaria Type Segment Breakdown
According to Analytical Market Research, based on Malaria Type Drug Class the market is segmented into plasmodium falciparum, plasmodium vivax, plasmodium malaria, and plasmodium ovale.
Anti-malarial Drugs Geographic Exploration
According to Analytical Market Research, the North America region is predicted to dominate the market, owing to the rise in the automotive industry in the region. Other regions competing in the market are North America, Europe, Middle East and Africa and Latin America respectively.

COMPETITIVE LANDSCAPE & RECENT DEVELOPMENT: Anti-malarial Drugs

The significant players rapidly evolve with new strategies to attain a competitive edge and capture significant market share.
• For Instance, in January 2021, MMV and GSK declared that the Australian Therapeutic Goods Administration (TGA) has accepted the filing of a Category 1 application aiming to include pediatric populations in the Kozenis single dosage (tafenoquine) indication expansion. The goal of this expansion is to treat Plasmodium vivax (P. vivax) malaria with a dramatic cure that stops relapses.

Noticeable Players Functioning in The Global Anti-malarial Drugs Market Include:

• Cadila Healthcare
• Cipla Limited
• GlaxoSmithKline Plc.
• Novartis AG
• Alvizia Healthcare
• Bayer AG
• Lincoln Pharmaceuticals Strides Pharma Science Limited
• Glenmark Pharmaceutical
• Alliance Pharma PLC..

KEY BREAKDOWN: Anti-malarial Drugs Market

By Drug Class:
• Aryl Aminoalcohol Compounds
• Antifolate Compounds
• Artemisinin Compounds
• Other
By Malaria Type:
• Plasmodium Falciparum
• Plasmodium Vivax
• Plasmodium Malaria
• Plasmodium Ovale
By Mechanism Of Action:
• Malaria
• Prevention From Malaria.
Geographical Exploration:
• North America
o The USA
o Canada
o Mexico
• Europe
o Germany
o France
o U.K.
o Russia
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o South Korea
o Australia
o New Zealand
o Singapore
o Malaysia
o Rest of Asia
• Latin America
o Brazil
o Argentina
o Colombia
o Peru
o Chile
o Venezuela
o Rest of Latin America
• Middle East and Africa
o Saudi Arabia
o UAE
o Egypt
o Kuwait
o South Africa
o Rest of Middle East & Africa

1. Research Methodology
1.1. Global Anti-malarial Drugs Market Snapshot, 2023 and 2030
1.2. Data Mining
1.3. Validation
1.4. Primary Interviews
1.5. List of Data Sources
1.6. Future Market Projections
1.7. Industry Developments and Key Market Events
2. Executive Summary
3. Market Overview
3.1. Market Scope and Definition
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunity
3.2.4. Challenges
3.2.5. Cumulative Impact due to Recent Energy Crisis
3.2.6. Cumulative Impact due to Nearing Economic Downturn
3.2.7. Post Covid-19 World Supply & Demand Conditions
3.2.8. Cumulative Impact of Russia-Ukraine Conflict
3.2.9. Key Trends
3.3. Anti-malarial Drugs Market: Value Chain
3.3.1. List of Raw Material Supplier
3.3.2. List of Manufacturers
3.3.3. List of Malaria Types
3.4. Porter Five Force’s Analysis
3.5. Regulatory and Technology Landscape
4. Global Anti-malarial Drugs Market Outlook: Forecast (2023 – 2030)
4.1. Key Highlights
4.1.1. Market Size and Y-o-Y Growth
4.1.2. Absolute $ Opportunity
4.2. Market Size (US$ Mn) Analysis and Forecast
4.2.1. Current Market Size Forecast, 2023–2030
4.3. Global Anti-malarial Drugs Market Outlook: Drug Class
4.3.1. Introduction / Key Findings
4.3.2. Market Size (US$ Mn) and Forecast Drug Class, 2023 – 2030
4.3.2.1. Aryl Aminoalcohol Compound
4.3.2.2. Antifolate Compounds
4.3.2.3. Artemisinin Compounds
4.3.2.4. Other
4.4. Global Anti-malarial Drugs Market Outlook: Malaria Type
4.4.1. Introduction / Key Findings
4.4.2. Market Size (US$ Mn) and Forecast By Malaria Type, 2023 – 2030
4.4.2.1. Plasmodium Falciparum
4.4.2.2. Plasmodium Vivax, Plasmodium Malaria
4.4.2.3. Plasmodium Ovale
4.5. Global Anti-malarial Drugs Market Outlook: Mechanism Of Action
4.5.1. Introduction / Key Findings
4.5.2. Market Size (US$ Mn) and Forecast By Mechanism Of Action, 2023 – 2030
4.5.2.1. Malaria
4.5.2.2. Prevention From Malaria.
5. Global Anti-malarial Drugs Market Outlook: Region
5.1. Key Highlights
5.2. Market Size (US$ Mn) and Forecast By Region, 2023 – 2030
5.2.1. North America
5.2.2. Europe
5.2.3. Asia Pacific
5.2.4. Latin America
5.2.5. Middle East & Africa (MEA)
6. North America Anti-malarial Drugs Market Outlook: Forecast (2023 – 2030)
6.1. Key Highlights
6.2. Pricing Analysis
6.3. Market Size (US$ Mn) and Analysis By Market, 2023 – 2022
6.3.1. By Country
6.3.2. By Drug Class
6.3.3. By Malaria Type
6.4. Market Size (US$ Mn) and Forecast By Country, 2023 – 2030
6.4.1. U.S.
6.4.2. Canada
6.4.3. Mexico
6.5. Market Size (US$ Mn) and Forecast By Drug Class, 2023 – 2030
6.5.1. Aryl Aminoalcohol Compound
6.5.2. Antifolate Compounds
6.5.3. Artemisinin Compounds
6.5.4. Other
6.6. Market Size (US$ Mn) and Forecast By Malaria Type, 2023 – 2030
6.6.1. Plasmodium Falciparum
6.6.2. Plasmodium Vivax, Plasmodium Malaria
6.6.3. Plasmodium Ovale
6.7. Market Size (US$ Mn) and Forecast By Mechanism Of Action, 2023 – 2030
6.7.1. Malaria
4.5.2. Prevention From Malaria
7. Europe Anti-malarial Drugs Market Outlook: Forecast (2023 – 2030)
7.1. Key Highlights
7.2. Pricing Analysis
7.3. Market Size (US$ Mn) and Analysis By Market, 2023 – 2030
7.3.1. By Country
7.3.2. By Drug Class
7.3.3. By Malaria Type
7.4. Market Size (US$ Mn) and Forecast By Country, 2023 – 2030
7.4.1. Germany
7.4.2. France
7.4.3. U.K.
7.4.4. Russia
7.4.5. Italy
7.4.6. Spain
7.4.7. Rest of Europe
7.5. Market Size (US$ Mn) and Forecast By Drug Class, 2023 – 2030
7.5.1. Aryl Aminoalcohol Compound
7.5.2. Antifolate Compounds
7.5.3. Artemisinin Compounds
7.5.4. Other
7.6. Market Size (US$ Mn) and Forecast By Malaria Type, 2023 – 2030
7.6.1. Plasmodium Falciparum
7.6.2. Plasmodium Vivax, Plasmodium Malaria
7.6.3. Plasmodium Ovale
7.7. Market Size (US$ Mn) and Forecast By Mechanism Of Action, 2023 – 2030
7.7.1. Malaria
4.5.2. Prevention From Malaria
8. Asia Pacific Anti-malarial Drugs Market Outlook: Forecast (2023 – 2030)
8.1. Key Highlights
8.2. Pricing Analysis
8.3. Market Size (US$ Mn) and Analysis By Market, 2023 – 2030
8.3.1. By Country
8.3.2. By Drug Class
8.3.3. By Malaria Type
8.4. Market Size (US$ Mn) and Forecast By Country, 2023 – 2030
8.4.1. China
8.4.2. Japan
8.4.3. India
8.4.4. South Korea
8.4.5. Australia
8.4.6. New Zealand
8.4.7. Singapore
8.4.8. Malaysia
8.4.9. Rest of Asia
8.5. Market Size (US$ Mn) and Forecast By Drug Class, 2023 – 2030
8.5.1. Aryl Aminoalcohol Compound
8.5.2. Antifolate Compounds
8.5.3. Artemisinin Compounds
8.5.4. Other
8.6. Market Size (US$ Mn) and Forecast By Malaria Type, 2023 – 2030
8.6.1. Plasmodium Falciparum
8.6.2. Plasmodium Vivax, Plasmodium Malaria
8.6.3. Plasmodium Ovale
8.7. Market Size (US$ Mn) and Forecast By Mechanism Of Action, 2023 – 2030
8.7.1. Malaria
4.5.2. Prevention From Malaria
9. Latin America Anti-malarial Drugs Market Outlook: Forecast (2023 – 2030)
9.1. Key Highlights
9.2. Pricing Analysis
9.3. Market Size (US$ Mn) and Analysis By Market, 2023 – 2030
9.3.1. By Country
9.3.2. By Drug Class
9.3.3. By Malaria Type
9.4. Market Size (US$ Mn) and Forecast By Country, 2023 – 2030
9.4.1. Brazil
9.4.2. Argentina
9.4.3. Colombia
9.4.4. Peru
9.4.5. Chile
9.4.6. Venezuela
9.4.7. Rest of Latin America
9.5. Market Size (US$ Mn) and Forecast By Drug Class, 2023 – 2030
9.5.1. Aryl Aminoalcohol Compound
9.5.2. Antifolate Compounds
9.5.3. Artemisinin Compounds
9.5.4. Other
9.6. Market Size (US$ Mn) and Forecast By Malaria Type, 2023 – 2030
9.6.1. Plasmodium Falciparum
9.6.2. Plasmodium Vivax, Plasmodium Malaria
9.6.3. Plasmodium Ovale
9.7. Market Size (US$ Mn) and Forecast By Mechanism Of Action, 2023 – 2030
9.7.1. Malaria
4.5.2. Prevention From Malaria
10. Middle East & Africa Anti-malarial Drugs Market Outlook: Forecast (2023 – 2030)
10.1. Key Highlights
10.2. Pricing Analysis
10.3. Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2023 – 2030
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Malaria Type
10.4. Market Size (US$ Mn) and Forecast By Country, 2023 – 2030
10.4.1. Saudi Arabia
10.4.2. UAE
10.4.3. Egypt
10.4.4. Kuwait
10.4.5. South Africa
10.4.6. Rest of Middle East & Africa
10.5. Market Size (US$ Mn) and Forecast By Drug Class, 2023 – 2030
10.5.1. Aryl Aminoalcohol Compound
10.5.2. Antifolate Compounds
10.5.3. Artemisinin Compounds
10.5.4. Other
10.6. Market Size (US$ Mn) and Forecast By Malaria Type, 2023 – 2030
10.6.1. Plasmodium Falciparum
10.6.2. Plasmodium Vivax, Plasmodium Malaria
10.6.3. Plasmodium Ovale
10.7. Market Size (US$ Mn) and Forecast By Mechanism Of Action, 2023 – 2030
10.7.1. Malaria
4.5.2. Prevention From Malaria
11. Competition Analysis
11.1. Market Share Analysis Of Top Vendors
11.2. Market Structure
11.2.1. Competition Intensity Mapping By Market
11.2.2. Competition Dashboard
11.2.3. Key Development Strategies
11.3. Company Profiles
11.3.1. Alliance Pharma PLC.
11.3.1.1. Overview
11.3.1.2. Offerings
11.3.1.3. Business Segment & Geographic Overview
11.3.1.4. Key Financials
11.3.1.5. Key Market Developments
11.3.1.6. Key Market Strategy
11.3.2. Cadila Healthcare
11.3.3. Cipla Limited
11.3.4. GlaxoSmithKline Plc.
11.3.5. Novartis AG
11.3.6. Alvizia Healthcare
11.3.7. Bayer AG
11.3.8. Lincoln Pharmaceuticals
11.3.9. Strides Pharma Science Limited
11.3.10. Glenmark Pharmaceuticals